| Literature DB >> 25756057 |
Marta Sacchetti1, Alessandro Lambiase2, Costanzo Moretti3, Flavio Mantelli4, Stefano Bonini5.
Abstract
PURPOSE: Vernal keratoconjunctivitis (VKC) is a chronic allergic disease mainly affecting boys in prepubertal age and usually recovering after puberty. To evaluate a possible role of sex hormones in VKC, serum levels of sex hormones in children and adolescents with VKC were assessed.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25756057 PMCID: PMC4324981 DOI: 10.1155/2015/945317
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Clinical characteristics of patients included in this study.
| Total | Prepuberty | Early puberty | Late puberty | |
|---|---|---|---|---|
| Patients | 25 | 12 | 7 | 6 |
| Atopic associated diseases ( | ||||
| Rhinitis | 2 | 0 | 2 | 0 |
| Asthma | 5 | 2 | 1 | 2 |
| Atopic dermatitis | 2 | 2 | 0 | 0 |
| Atopic dermatitis and asthma | 4 | 1 | 1 | 2 |
| None | 12 | 7 | 3 | 2 |
| Skin prick test ( | ||||
| Positive | 14 | 7 | 3 | 4 |
| Negative | 11 | 5 | 4 | 2 |
| Total IgE (U/mL) | 215 ± 257 | 323 ± 347 | 261 ± 189 | 111 ± 76 |
| Duration of VKC (years) | ||||
| Mean ± SD | 5.6 ± 3.4 | 3 ± 1.4 | 6.1 ± 2.2 | 10 ± 2.6 |
| VKC type ( | ||||
| Tarsal | 22 | 11 | 7 | 4 |
| Limbal | 3 | 1 | 0 | 2 |
| Mixed | 0 | 0 | 0 | 0 |
| VKC course | ||||
| Seasonal | 14 | 6 | 5 | 3 |
| Perennial | 11 | 6 | 2 | 3 |
| VKC grade | ||||
| 0—quiescent | 6 | 0 | 0 | 6 |
| 1—mild | 2 | 2 | 0 | 0 |
| 2—moderate | 9 | 6 | 3 | 0 |
| 3—severe | 4 | 1 | 3 | 0 |
| 4—very severe | 4 | 3 | 1 | 0 |
SD: standard deviation; VKC: vernal keratoconjunctivitis.
Sex hormones serum levels in active VKC and healthy subjects.
| Total | Prepubertal | Early pubertal | ||||
|---|---|---|---|---|---|---|
| VKC | Healthy | VKC | Healthy | VKC | Healthy | |
|
| 19 | 36 | 12 | 20 | 7 | 16 |
| Age | ||||||
| Mean ± SD | 8.7 ± 2 | 8.5 ± 2.9 | 7.3 ± 0.9 | 7 ± 1.3 | 11 ± 0.7 | 11 ± 1.1 |
| Range | 6–12 | 6–13 | 6–9 | 6–9 | 9–12 | 9–13 |
| LH (mUI/mL) | ||||||
| Mean ± SD | 0.5 ± 0.3 | 0.6 ± 0.5 | 0.4 ± 0.2 | 0.4 ± 0.2 | 0.9 ± 0.5 | 0.8 ± 0.5 |
| Range | 0.2–1.2 | 0.1–2 | 0.2–0.7 | 0.1–0.8 | 0.5–1.2 | 0.1–2 |
| FSH (mUI/mL) | ||||||
| Mean ± SD | 0.7 ± 0.5* |
| 0.6 ± 0.4 | 1 ± 0.6 | 0.8 ± 0.6* |
|
| Range |
|
| 0.3–1.2 | 0.2–3 |
|
|
| Total testosterone (ng/100 mL) | ||||||
| Mean ± SD | 28.7 ± 47 | 18 ± 12 | 13 ± 9.1 | 9.8 ± 4.2 | 36 ± 24 | 26 ± 12 |
| Range | 1–73 | 4–48 | 1–27 | 4–17 | 7–73 | 6–48 |
| Free testosterone (ng/100 mL) | ||||||
| Mean ± SD | 2.7 ± 4.7* |
| 2 ± 2.8* |
| 4.1 ± 7.4 | 1.6 ± 1 |
| Range |
|
|
|
| 0.5–19.2 | 0.2–4.9 |
| DHT (pg/mL) | ||||||
| Mean ± SD | 17 ± 11.7 | 41.7 ± 36.3 | 15 ± 8.7* |
| 21 ± 19* |
|
| Range | 3–38 | 15–140 |
|
|
|
|
| Estradiol (pg/mL) | ||||||
| Mean ± SD | 14.7 ± 6.8 | 17.7 ± 5.5 | 14.9 ± 7.2 | 17.4 ± 4.9 | 14.2 ± 6.7 | 17.9 ± 6 |
| Range | 5–29 | 10–34 | 5–29 | 10–27 | 10–24 | 10–34 |
| Estrone (pg/mL) | ||||||
| Mean ± SD | 33.8 ± 18.8* |
| 33.7 ± 3.5* |
| 34.5 ± 3.5* |
|
| Range |
|
|
|
|
|
|
| DHEAS (ng/mL) | ||||||
| Mean ± SD | 855 ± 1008 | 612 ± 221 | 707 ± 685 | 488 ± 186 | 1111 ± 1440 | 731 ± 186 |
| Range | 87–2640 | 132–1200 | 87–2190 | 132–861 | 273–2640 | 358–1200 |
| D4A (ng/mL) | ||||||
| Mean ± SD | 0.7 ± 0.7 | 0.7 ± 0.3 | 0.7 ± 0.8 | 0.5 ± 0.2 | 0.9 ± 0.4 | 0.9 ± 0.4 |
| Range | 0.1–2.5 | 0.3–2.2 | 0.1–2.5 | 0.3–0.9 | 0.6–1.2 | 0.6–2.2 |
| Cortisol (ng/mL) | ||||||
| Mean ± SD | 122 ± 73 | 102 ± 49 | 138 ± 80 | 107 ± 55 | 79 ± 28 | 96 ± 41 |
| Range | 31–238 | 35–205 | 31–238 | 35–205 | 51–107 | 45–197 |
| SHBG (nmol/L) | ||||||
| Mean ± SD |
| 120 ± 19* | 76.6 ± 42.6* |
| 41.7 ± 25* |
|
| Range |
|
|
|
|
|
|
VKC: vernal keratoconjunctivitis; * P < 0.05; N: number; SD: standard deviation; LH: luteinizing hormone; FSH: follicle-stimulating hormone; DHT: dihydrotestosterone; DHEAS: dehydroepiandrosterone-sulfate; D4A: delta-4-androstenedione; SHBG: sex hormones binding globulin.
Sex hormones serum levels in patients with VKC in remission phase compared to healthy subjects.
| Late puberty | ||
|---|---|---|
| VKC | Healthy | |
|
| 6 | 12 |
| Age | ||
| Mean ± SD | 14–17 | 14–17 |
| Range | 15.3 ± 1 | 15.7 ± 1 |
| LH (mUI/mL) | ||
| Mean ± SD | 2.7 ± 0.6 | 2.6 ± 1.4 |
| Range | 2.1–3.5 | 1.1–5.4 |
| FSH (mUI/mL) | ||
| Mean ± SD | 5.8 ± 3.8 | 5.2 ± 1.5 |
| Range | 1.4–8.2 | 2.9–9.8 |
| Total testosterone (ng/100 mL) | ||
| Mean ± SD | 369 ± 142 | 369 ± 142 |
| Range | 202–593 | 254–789 |
| Free testosterone (ng/100 mL) | ||
| Mean ± SD | 17.1 ± 42* |
|
| Range |
|
|
| DHT (pg/mL) | ||
| Mean ± SD | 362 ± 37 | 445 ± 89 |
| Range | 320–386 | 289–593 |
| Estradiol (pg/mL) | ||
| Mean ± SD | 21 ± 9 | 27 ± 7 |
| Range | 15–37 | 19–41 |
| Estrone (pg/mL) | ||
| Mean ± SD | 36.5 ± 7* |
|
| Range |
|
|
| DHEAS (ng/mL) | ||
| Mean ± SD | 1131 ± 700* |
|
| Range |
|
|
| D4A (ng/mL) | ||
| Mean ± SD | 1.4 ± 0.5 | 1.6 ± 0.3 |
| Range | 1–2.2 | 1.1–2.1 |
| Cortisol (ng/mL) | ||
| Mean ± SD | 130 ± 63 | 119 ± 37 |
| Range | 56–209 | 76–203 |
| SHBG (nmol/L) | ||
| Mean ± SD | 73 ± 44* |
|
| Range |
|
|
VKC: vernal keratoconjunctivitis; * P < 0.05; N: number; SD: standard deviation; LH: luteinizing hormone; FSH: follicle-stimulating hormone; DHT: dihydrotestosterone; DHEAS: dehydroepiandrosterone-sulfate; D4A: delta-4-androstenedione; SHBG: sex hormones binding globulin.